ADVANT Altana

PRESS RELEASE

ADVANT Altana advises the sale of control of Kurma Partners to Eurazeo

Paris, January 3^{rd,} 2022 – The shareholders of Kurma Partners, an investment management company specializing in financing innovation in healthcare and biotechnology, have sold a controlling interest to Eurazeo. This transaction allows Kurma Partners to pursue its development strategy and to launch a third family of funds with a first growth vehicle. This initiative is supported by Eurazeo, which has become one of Kurma Partners' reference investors and will invest significantly in its next vehicles, namely Growth Opportunity I and Kurma Biofund IV.

Eurazeo becomes one of the reference investors of the funds managed by Kurma Partners and will support the launch of its new crossover financing strategy to support the most promising European companies in the more advanced stages of development.

Eurazeo will also provide operational support and access to its international network to help Kurma Partners become a European leader in the field of medical innovation. Kurma Partners will retain its management autonomy with an unchanged management team.

In this transaction, ADVANT Altana has combined its M&A expertise with its in-depth knowledge of the healthcare sector, in which the expertise of the firm's lawyers is particularly well known.

In this transaction, Kurma Partners was advised by ADVANT Altana, with a team composed of Jean-Nicolas Soret, Géraldine Malfait and Léonie Bontoux. Eurazeo was advised by Bredin Prat.

About Kurma Partners

Founded in July 2009, Kurma Partners is a Paris-based management company specializing in the financing innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II and III funds and the Kurma Diagnostics and Kurma Diagnostics 2 funds, is one of the leading players in the financing of therapeutic and medical innovations in Europe, in particular through the links it has forged with numerous prestigious research institutes and hospitals.

About Eurazeo

Eurazeo is a leading global investment company with €25.6 billion of diversified assets under management, including €17.8 billion invested on behalf of third parties in a portfolio of more than 450 companies. With expertise in private equity, real estate and private debt, the Group supports companies of all sizes through the commitment of its nearly 300 employees, its deep sector experience, its privileged access to global markets, and its responsible approach to value creation based on growth. Its institutional and family shareholding, its solid financial structure without structural debt and its flexible investment horizon enables it to support companies over the long term.

Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai, Singapore, London, Luxembourg, Frankfurt, Berlin, and Madrid. Eurazeo is listed on Euronext Paris.

About ADVANT Altana

About ADVANT Altana ADVANT Altana is a multi-practice law firm founded in 2009, with more than 80 lawyers and attorneys, including 22 partners. ADVANT Altana's teams assist French and foreign companies, as well as their managers, in the handling of high stakes technical or strategic cases, particularly in the most regulated sectors: Banking-Insurance, Construction, Renewable Energies, Life Sciences, TMT (Technologies - Media - Telecommunications).

ADVANT Altana is a member of ADVANT, an association of continental European law firms comprising ADVANT Altana in France, ADVANT Beiten in Germany and ADVANT Nctm in Italy.

Press contacts:

Gantzer Agency

Juliette Rohmer + 33 7 60 21 20 34 julietterohmer@gmail.com

Advant Altana – Communications Department

Dominique Chanteux-Gillet +33 1 85609001 dominique.chanteux-gillet@advant-altana.com